Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

Conclusions: Our results indicate that early development of rash identifies patients who derive superior benefit from lapatinib-based therapy.

Source: JNCI - April 19, 2016 Category: Cancer & Oncology Authors: Sonnenblick, A., de Azambuja, E., Agbor-tarh, D., Bradbury, I., Campbell, C., Huang, Y., Dueck, A. C., Pritchard, K. I., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Perez, E. A., Piccart, M., Azim, H. A. Tags: Article Source Type: research